Cargando…

A thermostable, chromatographically purified Ebola nano-VLP vaccine

BACKGROUND: Filovirus virus-like particles (VLP) are strong immunogens with the potential for development into a safe, non-infectious vaccine. However, the large size and filamentous structure of this virus has heretofore made production of such a vaccine difficult. Herein, we present new assays and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carra, John H, Martins, Karen A O, Schokman, Rowena D, Robinson, Camenzind G, Steffens, Jesse T, Bavari, Sina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502941/ https://www.ncbi.nlm.nih.gov/pubmed/26174690 http://dx.doi.org/10.1186/s12967-015-0593-y

Ejemplares similares

T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection
por: Cooper, Christopher L, et al.
Publicado: (2017)

Toll-Like Receptor Agonist Augments Virus-Like Particle-Mediated Protection from Ebola Virus with Transient Immune Activation
por: Martins, Karen A. O., et al.
Publicado: (2014)

Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)
por: Dye, John M., et al.
Publicado: (2016)

Discovering Drugs for the Treatment of Ebola Virus
por: Bixler, Sandra L., et al.
Publicado: (2017)

Surface-immobilization of chromatographically purified bacteriophages for the optimized capture of bacteria
por: Naidoo, Ravendra, et al.
Publicado: (2012)

Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology
por: Johnson, Reed F, et al.
Publicado: (2006)

RNA Phage VLP-Based Vaccine Platforms
por: Peabody, David S., et al.
Publicado: (2021)

Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
por: Chanthavanich, Pornthep, et al.
Publicado: (2018)

Virus-like particle (VLP)-based vaccines for pandemic influenza: Performance of a VLP vaccine during the 2009 influenza pandemic
por: López-Macías, Constantino
Publicado: (2012)

Mechanisms of Immunity in Post-Exposure Vaccination against Ebola Virus Infection
por: Bradfute, Steven B., et al.
Publicado: (2015)

Zika virus-like particle (VLP) based vaccine
por: Boigard, Hélène, et al.
Publicado: (2017)

Large-scale production and purification of VLP-based vaccines
por: Vicente, Tiago, et al.
Publicado: (2011)

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
por: Ruzzi, Francesca, et al.
Publicado: (2023)

Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus
por: Warren, Travis K., et al.
Publicado: (2021)

Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine
por: Hankaniemi, Minna M., et al.
Publicado: (2020)

Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity
por: Martins, Karen A.O., et al.
Publicado: (2015)

Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations
por: Cazares, Lisa H., et al.
Publicado: (2016)

Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements
por: Yu, Dong-Shan, et al.
Publicado: (2018)

The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine
por: Torresi, Joseph
Publicado: (2017)

A DNA inducing VLP vaccine designed for HIV and tested in mice
por: Calazans, Alexandre, et al.
Publicado: (2017)

VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases
por: Queiroz, Aline Maria Vasconcelos, et al.
Publicado: (2021)

Corrigendum: Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements
por: Yu, Dong-Shan, et al.
Publicado: (2020)

Interaction between Borrelia miyamotoi variable major proteins Vlp15/16 and Vlp18 with plasminogen and complement
por: Schmidt, Frederik L., et al.
Publicado: (2021)

In Vivo and In Vitro Characterization of Provodine, a Long Acting, Alcohol-Free Professional Antiseptic, Against Ebola Virus and Other Serious Viral, Bacterial and Fungal Pathogens
por: Lentini, Peter, et al.
Publicado: (2015)

Retraction: A DNA inducing VLP vaccine designed for HIV and tested in mice
Publicado: (2018)

VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation
por: Daly, Seth M., et al.
Publicado: (2017)

Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus
por: Mobini, Saeed, et al.
Publicado: (2020)

A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines
por: Goksøyr, Louise, et al.
Publicado: (2022)

On the Effect of Thermodynamic Equilibrium on the Assembly Efficiency of Complex Multi-Layered Virus-Like Particles (VLP): the Case of Rotavirus VLP
por: Roldão, António, et al.
Publicado: (2012)

VLP‐factory™ and ADDomer(©): Self‐assembling Virus‐Like Particle (VLP) Technologies for Multiple Protein and Peptide Epitope Display
por: Sari‐Ak, Duygu, et al.
Publicado: (2021)

Genome-Wide Search for Competing Endogenous RNAs Responsible for the Effects Induced by Ebola Virus Replication and Transcription Using a trVLP System
por: Wang, Zhong-Yi, et al.
Publicado: (2017)

Erythro-VLP: Erythrocyte Virus-Like-Particles
por: Himbert, Sebastian, et al.
Publicado: (2021)

Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics
por: Warren, Travis, et al.
Publicado: (2020)

Assembly of Ebola Virus Matrix Protein VP40 Is Regulated by Latch-Like Properties of N and C Terminal Tails
por: Silva, Leslie P., et al.
Publicado: (2012)

Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses
por: Schellenbacher, Christina, et al.
Publicado: (2013)

Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer
por: Donaldson, Braeden, et al.
Publicado: (2017)

DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines
por: Cabral-Miranda, Gustavo, et al.
Publicado: (2018)

A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development
por: Atcheson, Erwan, et al.
Publicado: (2021)

VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
por: Prates-Syed, Wasim A., et al.
Publicado: (2021)

The Immunogenicity of a VLP-based Malaria Vaccine Targeting CSP in Pregnant and Neonatal Mice
por: Jelínková, Lucie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ov69961jgkk71hnjbjpo9vm8me